Total prescription demand increased in 2015 to 4.4Bn1 with 50-75% not working as intended2 Every year, more than 8.6 million adverse drug events (ADEs) are reported in the U.S., 2.2 million of them are severe causing 700,000+ deaths and 120,000+ hospitalizations. In fact, ADEs are the fourth leading cause of death Nationwide3, after heart disease, cancer and stroke, and they place an enormous financial burden on the healthcare system. Even with proper prescribing, a patient’s genes can affect how they metabolize and respond to drugs. More than 85% of patients have detectable variations in their DNA that affect their response to drugs and increase their risk for an ADEs 4,5.
By identifying which inherited genetic variations a patient has will
Anyone can take the test, however, this test offers clinicians the ability to personalize drug therapy and increase safety and compliance in the most challenging cases such as
Giving physicians the necessary tools to select the proper drug therapy for their patients, at the proper dose, while avoiding unnecessary side effects.
Provides clinicians access to information for gene-guided prescription drugs widely used in medicine:
Medreview is a genetic assessment of the medicines currently prescribed or being considered for the patient. Medreview provides an easy to comprehend report immediately identifying areas of concern for the physician specific to the patient’s medication list and their pharmacogenetics disposition. Appropriate alternative therapies are identified, dosing guidance and drug/drug interactions provided.
Medreview is used for patients on multi-drug regimens for the common diseases in general medicine and mental health: blood pressure, cholesterol, heart attacks, depression, diabetes, asthma, heartburn,inflammation, blood clots, pain management, acid reflux, sexual dysfunction, addiction, diabetes, and sleep.
| Category | Drug | Use as Directed | Use with Caution | Consider Alternatives | Drug Interactions |
|---|---|---|---|---|---|
| 5 Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia | Dutasteride | ✔ | |||
| Finasteride | |||||
| Alpha-Blockers for Benign Prostatic Hyperplasia | Alfuzosin | ✔ | ! Fluconazole | ||
| Duxazosin | ✔ | ||||
| Silodosin | ✔ | ||||
| Tamsulosin | ✔ | ||||
| Terazosin | ✔ | ||||
| Angiotensin II Receptor Antagonists | Irbesartan | ✔ | !! Bactrim | ||
| Antiaddictives | Bupropion | ! | ! Bupropion !! Rifadin |
STEP1 Clinician orders the Genesys Pharmacogenomics Test for patient
STEP2 Clinician conducts the Test in office and FedEx Pre-paid to Lab
STEP3 Genesys processes the sample and sends Pharmacogenomics Test Report to Clinician
Medical Management Panel: (CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP2C9, VKORC1, CYP3A4, CYP3A5, OPRM1, COMT, ANKK1/DRD2, Factor II, Factor V, MTHFR, APOE, SLCO1B1)
Psychiatry Panel: (CYP1A2, CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5, COMT, ANKK1/DRD2)
Pain Management Panel: (CYP1A2, CYP2D6, CYP2C19, CYP3A4, CYP3A5, CYP2B6, CYP2C9, OPRM1, Factor II, Factor V, MTHFR)
Neurology Panel: (CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP2C9, COMT, OPRM1)
Cardiovascular Panel: (CYP2C19, CYP2D6, CYP2C9, VKORC1, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR, APOE, SLCO1B1)
Orthopedic Panel: (CYP2D6, CYP2C19, VKORC1, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR)
Gastrointestinal Panel: (CYP2D6, CYP2C19)
Urological Panel: (CYP2D6)
| Description | Genesys Diagnostics Inc. Pharmacogenetics |
|---|---|
| Method | Multiplex Bead Array |
| Specimen Requirements | Buccal Swab |
| Turnaround Time | 5-7 Days |
| Shipping | Pickup/Fedex Service Available Monday – Friday |
| Testing Performed | Monday-Saturday |